U.S. Approves World’s First GMO Wheat Grown with Banned Neurotoxic Herbicide

The AHA! Team — Mon, 23 Jun 2025 20:30:56 +0000

Stephanie Woods via NaturalHealth365 – While corporations and even our government tamper with our food, yet another addition is making its way to U.S. soil. The U.S. Department of Agriculture (USDA) recently approved the cultivation of genetically modified (GM) wheat. The first GM wheat in the world comes from Bioceres, an Argentinean company, and French company Florimond Desprez. While Argentina is currently the “only” place where GM wheat products are being consumed, this toxic food is heading to the United States. The movement to deregister GM wheat products is strong and relentless. It will eventually happen, likely sooner rather than later. To avoid this, it is a good idea to begin preparations now. The hidden dangers of glufosinate ammonium One of the biggest concerns about GMO wheat is that it is grown with glufosinate ammonium. This highly dangerous agrotoxin has been banned in the European Union due to its serious health risks. Exposure to glufosinate ammonium has been linked to a range of concerning health impacts, including gastrointestinal issues such as mouth ulcers, abdominal pain, nausea, vomiting, diarrhea, and sore throat. Cardiovascular problems like low blood pressure (hypotension) and slow heart rate (bradycardia) have also been reported. Neurological effects can range from drowsiness, headaches, agitation, tremors, stupor, confusion, and dizziness to severe outcomes like seizures, retrograde amnesia, coma, and even respiratory failure. Additionally, respiratory complications such as hypoxia and shortness of breath pose significant threats. Given these alarming risks, it’s clear that we must actively avoid products containing this harmful chemical. Unfortunately, we cannot rely on government agencies to protect us; their actions often suggest the opposite. We must stay informed, make conscious choices, and take control of our health and well-being. Too many red flags to ignore! When it comes to GM wheat, the red flags are impossible to overlook. For starters, no publicly available studies or documentation prove its safety. Despite being heavily promoted as “drought resistant,” no credible evidence supports this claim. In fact, GM wheat hasn’t even demonstrated higher productivity compared to conventional wheat. The situation in Argentina highlights another major concern. The country’s National Commission on Biotechnology, the central authority responsible for approving GM foods, is largely made up of representatives from companies that profit from selling GMOs. With such an obvious conflict of interest, there are virtually no checks and balances in place to ensure transparency or accountability. These glaring issues make it clear that GM wheat comes with far more questions than answers. How to avoid GM wheat: Take control of your food choices Avoiding GM wheat is entirely possible with some mindful shopping habits. One of the most effective strategies is to buy organic. Foods with the Certified Organic seal are prohibited from containing GMOs, offering a reliable safeguard against genetically modified ingredients. When shopping, look for the Non-GMO Project Verified seal. While many products claim to be “non-GMO,” this official certification ensures a higher standard of transparency and accountability, giving you greater confidence in your purchases. Another essential step is to avoid processed foods. Whole, organic foods are far less likely to contain GMOs, while processed foods are notorious for sneaking them in through various additives and fillers. Whenever possible, buy directly from local farms. This supports the local economy, allows you to ask questions about farming practices, and helps to ensure you get clean, high-quality food. The reality is that the tampering with our food supply isn’t likely to stop anytime soon. Governments and large corporations often prioritize profit and convenience over nutrition and public health. That means it’s up to us to take matters into our own hands – to educate ourselves, make informed choices, and seek out healthy alternatives to the heavily processed, GMO-laden products they want to push on us. It’s time to stand firm. Every purchase is a choice, a step towards reclaiming control over our health. Push back. Choose better. Sources for this article include: Childrenshealthdefense.org Sciencedirect.com NIH.gov To read the original article click here.

The post U.S. Approves World’s First GMO Wheat Grown with Banned Neurotoxic Herbicide appeared first on Amazing Health Advances.

A Potential New Treatment for Brain Tumors

AHA Publisher — Wed, 28 Sep 2022 07:00:11 +0000

University of Cincinnati via Newswise – A research question posed in Pankaj Desai’s lab has led to a decade of research, a clinical trial and major national funding to further investigate a potential new treatment for the most deadly form of brain tumors. Desai, PhD, and his team at the University of Cincinnati recently received a $1.19 million grant from the National Institutes of Health/National Institute of Neurological Disorders and Stroke to continue research into the use of a drug called letrozole to treat glioblastomas (GBM). Research Progression GBMs are aggressive brain tumors that patients often are unaware of until symptoms emerge and the tumor is substantial. Current treatments include immediate surgery to safely remove as much tumor as possible, radiation and chemotherapy, but the tumor often recurs or becomes resistant to treatments. The average patient survives no more than 15 months after diagnosis. The medication letrozole was approved by the U.S. Food and Drug Administration as a treatment for postmenopausal women with breast cancer in 2001. The drug works by targeting an enzyme called aromatase that is present in breast cancer cells and helps the cancer grow. In the fall of 2012, Desai and a doctoral student in his lab, Nimita Dave (now a senior pharmacologist at a biotech company in Boston), asked a question: Does aromatase play a similar role in GBM tumors, and if so, will letrozole work as an effective treatment? Early research in the lab found the enzyme was present in brain tumor cell lines, and further testing found a very high amount of aromatase at protein and mRNA levels in brain tumor samples from UC’s tumor bank. However, that did not guarantee that letrozole would be similarly effective in brain tumors like it is in breast cancer tumors. Desai explained a defense system called the blood-brain barrier only allows certain compounds into the brain based on their physical and chemical properties. “Otherwise any compound could come into the brain and cause havoc and neurotoxicity,” said Desai, professor and chair of the Pharmaceutical Sciences Division in UC’s James L. Winkle College of Pharmacy and a University of Cincinnati Cancer Center member. “There are other compounds similar to letrozole, but we went with letrozole because we figured that based on its properties, this compound actually has the best chance of getting through into the brain from the blood circulation.” Studies in animal models showed that letrozole was effective, and Desai’s research group moved to test the compound in cells derived from human brain tumor tissues. In this phase of work, key contributions were made by current doctoral student Aniruddha Karve who will continue to work with Desai as a postdoctoral fellow on the new NIH grant. “What we saw in the patient-derived cells is that letrozole is very effective in killing the tumor cells in cell culture models,” Desai said. With funding support from the Cancer Center and the UC Brain Tumor Center, Desai’s team launched a phase 0/1 clinical trial testing what dosage of letrozole is appropriate to treat glioblastomas. This trial was led by Trisha Wise-Draper, MD, PhD, an expert in phase 1 oncology trials with contributions from several other neuro-oncologists and neurosurgeons. The trial is set to be completed soon, but Desai said early results have shown the drug is “unequivocally” reaching its target of the brain tumor tissue safely. Preliminary results also show that doses of letrozole higher than those needed for breast cancer treatment can be safely achieved in GBM patients. New Research While the body of research results has been encouraging so far, Desai said GBMs remain a complicated, aggressive form of brain cancer. As promising as letrozole is, it is still unlikely that the drug will be a singular cure for the disease. “We hope that would work, but it’s not necessarily rooted in reality. It’s going to be a combination of drugs,” Desai said. Supported by the new NIH/NINDS funding, Desai and his team will research the preclinical effectiveness of combining letrozole with other chemotherapy compounds. The three-year grant began Aug. 1. “It’s really exciting to get this sort of reassurance from a peer reviewed grant application,” Desai said. “And it’s an exciting time. I think finding a cure for a disease like GBM is like finding a needle in a haystack, and we hope that it’s going to really work, and that’s what we are all striving for.” Desai said the research has been and continues to be a collaborative effort between UC colleagues from the College of Pharmacy, Cancer Center and Brain Tumor Center. “It’s really a beautiful collaboration, and I’m most grateful for that,” Desai said. “This is a disease where an urgent breakthrough is absolutely needed, and our team along with others in the field are really striving to make a difference.” David Plas, PhD, professor and Anna and Harold W. Huffman endowed chair in glioblastoma experimental therapeutics in the Department of Cancer Biology in UC’s College of Medicine and a Cancer Center member, and his research group are joining the team as the new project launches. Plas said his lab has focused on tumors deficient in a tumor-suppressing protein called PTEN, and the new research may reveal how letrozole in combination with other therapies may lead to a suitable treatment for PTEN-deficient glioblastomas. “This new collaboration will combine my group’s experience in glioblastoma experimental therapeutics with Dr. Desai’s experience in GBM therapeutics and pharmacokinetics,” Plas said. “By investigating possible combinations with letrozole for GBM therapy, this new project has the potential for faster translation to clinical trial. It is exciting to work with Desai on this new project.” To read the original article click here.

The post A Potential New Treatment for Brain Tumors appeared first on Amazing Health Advances.

neurotoxicity Archives - Amazing Health Advances

U.S. Approves World’s First GMO Wheat Grown with Banned Neurotoxic Herbicide

A Potential New Treatment for Brain Tumors